title: Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat.
abstract: The aim of this study was developing colon targeted-delivery of budesonide for ulcerative colitis. Microcapsules were prepared using spray drying technique by different drug-to-dextran ratios and three molecular weights (MWs) of polymer. Differential scanning calorimetry, X-ray diffraction (XRD), drug release and loading efficiency of microcapsules were studied. In vivo efficacy of the selected formulation prepared by 1 : 10 drug-to-polymer ratio and dextran with MW 500 000 (D10M500) against acetic acid-induced colitis in rats was evaluated and compared to the control and reference groups (mesalasine and budesonide suspensions). The results showed that D10M500 microcapsules could target the drug to colon and its efficacy in reducing macroscopic damage score was higher than mesalasine suspension. Treatment with D10M500 decreased the scores of crypt damage and total colitis significantly compared to the control group which just received the vehicle and the groups treated with mesalasine and budesonide suspension which could not reduce the colitis parameters significantly.
authors.affiliation: Department of Pharmaceutics and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. varshosaz@pharm.mui.ac.ir
authors.forename: Jaleh
authors.initials: J
authors.lastname: Varshosaz
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Ahmadi
authors.forename: Jaber
authors.initials: J
authors.lastname: Emami
authors.forename: Naser
authors.initials: N
authors.lastname: Tavakoli
authors.forename: Mohsen
authors.initials: M
authors.lastname: Minaiyan
authors.forename: Parvin
authors.initials: P
authors.lastname: Mahzouni
authors.forename: Farid
authors.initials: F
authors.lastname: Dorkoosh
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage* / Q000627:therapeutic use; D002152:Calorimetry, Differential Scanning; D002214:Capsules / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D003890:Desiccation; D003911:Dextrans / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D016503:Drug Delivery Systems; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014961:X-Ray Diffraction
chemical_list: D000893:Anti-Inflammatory Agents; D002214:Capsules; D003911:Dextrans; D019819:Budesonide